Skip to content

Released Aug 3, 2023, before the open

10-Q filed Aug 3, 2023, 34 days after period end · 0001171843-23-004947

Q2 2023 · 10-Q
Revenue$0.00no prior Q2 2022 on fileno prior Q1 2023 on file
Net Income-$11.28MN/M vs Q2 2022N/M vs Q1 2023
EPS, diluted—
Operating Income-$13,337,000N/M
Operating Cash Flowderived-$10,113,000N/M
Free Cash Flowderived-$10,124,000N/M

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$0.00———
Net Income-$11.28M-$8.49M-$55.80M-$5.56M
EPS Diluted——-$1.07-$0.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR